Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 760500
                    [Title] => New indication timely gift for type 2 diabetes patients
                    [Summary] => 
With the many sumptuous feasts and gastronomic temptations it brings, the Christmas season is often a dilemma for patients with diabetes trying to keep their blood sugar level in check.
                    [DatePublished] => 2011-12-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 719783
                    [Title] => Arthritis drug launched
                    [Summary] => 
Pain relief for patients with chronic arthritis has always been problematic because non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely prescribed agents for these conditions, cause gastrointestinal side effects such as stomach ulcers.
                    [DatePublished] => 2011-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 638698
                    [Title] => Gird up against GERD
                    [Summary] => 
You can be a candidate for GERD this holiday season. GERD is the acronym for gastro-esophageal reflux disease, a condition where gastric juices containing acid travel back from the stomach to the esophagus.
                    [DatePublished] => 2010-12-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1422176
                    [AuthorName] => Joy Angelica  Subido
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 630709
                    [Title] => Better GERD diagnosis, treatment pushed
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca is working with specialists to “localize” a patient questionnaire that can help primary care physicians better diagnose gastroesophageal reflux disease (GERD), a common digestive disorder that is often undiagnosed, untreated and improperly managed.
                    [DatePublished] => 2010-11-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 626492
                    [Title] => AstraZeneca's gefitinib gets FDA approval
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 603626
                    [Title] => Partnership forged to curb diabetes cases
                    [Summary] => 
Alarmed at the growing prevalence of diabetes in the country, societies dealing with the epidemic of type 2 diabetes, including the American Association of Clinical Endocrinologists (AACE) Philippine Chapter and Diabetes Philippines (DP), have partnered with research-based biopharmaceutical company AstraZeneca to increase public awareness on diabetes prevention and management.
                    [DatePublished] => 2010-08-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 584585
                    [Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
                    [Summary] => 
Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
                    [DatePublished] => 2010-06-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 530595
                    [Title] => AstraZeneca 'personalized healthcare' customizes treatments for patients
                    [Summary] => 
Guided by a better understanding of diseases and the differences among patients, one of the world’s leading pharmaceutical companies, AstraZeneca, is adopting a “personalized” approach to healthcare, particularly in developing targeted cancer treatments.
                    [DatePublished] => 2009-12-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 14809
                    [Title] => Novartis gears up for Biocamp 2007
                    [Summary] => 
            
                    [DatePublished] => 2007-08-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

AMAL KELSHIKAR

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 760500
                    [Title] => New indication timely gift for type 2 diabetes patients
                    [Summary] => 
With the many sumptuous feasts and gastronomic temptations it brings, the Christmas season is often a dilemma for patients with diabetes trying to keep their blood sugar level in check.
                    [DatePublished] => 2011-12-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 719783
                    [Title] => Arthritis drug launched
                    [Summary] => 
Pain relief for patients with chronic arthritis has always been problematic because non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely prescribed agents for these conditions, cause gastrointestinal side effects such as stomach ulcers.
                    [DatePublished] => 2011-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 638698
                    [Title] => Gird up against GERD
                    [Summary] => 
You can be a candidate for GERD this holiday season. GERD is the acronym for gastro-esophageal reflux disease, a condition where gastric juices containing acid travel back from the stomach to the esophagus.
                    [DatePublished] => 2010-12-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1422176
                    [AuthorName] => Joy Angelica  Subido
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 630709
                    [Title] => Better GERD diagnosis, treatment pushed
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca is working with specialists to “localize” a patient questionnaire that can help primary care physicians better diagnose gastroesophageal reflux disease (GERD), a common digestive disorder that is often undiagnosed, untreated and improperly managed.
                    [DatePublished] => 2010-11-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 626492
                    [Title] => AstraZeneca's gefitinib gets FDA approval
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 603626
                    [Title] => Partnership forged to curb diabetes cases
                    [Summary] => 
Alarmed at the growing prevalence of diabetes in the country, societies dealing with the epidemic of type 2 diabetes, including the American Association of Clinical Endocrinologists (AACE) Philippine Chapter and Diabetes Philippines (DP), have partnered with research-based biopharmaceutical company AstraZeneca to increase public awareness on diabetes prevention and management.
                    [DatePublished] => 2010-08-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 584585
                    [Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
                    [Summary] => 
Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
                    [DatePublished] => 2010-06-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 530595
                    [Title] => AstraZeneca 'personalized healthcare' customizes treatments for patients
                    [Summary] => 
Guided by a better understanding of diseases and the differences among patients, one of the world’s leading pharmaceutical companies, AstraZeneca, is adopting a “personalized” approach to healthcare, particularly in developing targeted cancer treatments.
                    [DatePublished] => 2009-12-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 14809
                    [Title] => Novartis gears up for Biocamp 2007
                    [Summary] => 
            
                    [DatePublished] => 2007-08-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

New indication timely gift for type 2 diabetes patients

December 22, 2011 - 12:00am

With the many sumptuous feasts and gastronomic temptations it brings, the Christmas season is often a dilemma for patients with diabetes trying to keep their blood sugar level in check.

Science and Environment

Arthritis drug launched

August 25, 2011 - 12:00am

Pain relief for patients with chronic arthritis has always been problematic because non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely prescribed agents for these conditions, cause gastrointestinal...

Science and Environment

Gird up against GERD

By Joy Angelica Subido | December 14, 2010 - 12:00am

You can be a candidate for GERD this holiday season. GERD is the acronym for gastro-esophageal reflux disease, a condition where gastric juices containing acid travel back from the stomach to the esophagus.

Health And Family

Better GERD diagnosis, treatment pushed

November 18, 2010 - 12:00am

Research-based pharmaceutical company AstraZeneca is working with specialists to “localize” a patient questionnaire that can help primary care physicians better diagnose gastroesophageal reflux disease...

Science and Environment

AstraZeneca's gefitinib gets FDA approval

November 4, 2010 - 12:00am

Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive...

Science and Environment

Partnership forged to curb diabetes cases

August 19, 2010 - 12:00am

Alarmed at the growing prevalence of diabetes in the country, societies dealing with the epidemic of type 2 diabetes, including the American Association of Clinical Endocrinologists (AACE) Philippine Chapter and...

Science and Environment

AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management

June 17, 2010 - 12:00am

Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall...

Science and Environment

AstraZeneca 'personalized healthcare' customizes treatments for patients

December 10, 2009 - 12:00am

Guided by a better understanding of diseases and the differences among patients, one of the world’s leading pharmaceutical companies, AstraZeneca, is adopting a “personalized” approach to healthcare,...

Science and Environment

Novartis gears up for Biocamp 2007

August 23, 2007 - 12:00am

Science and Environment